A switchable NO-releasing nanomedicine for enhanced cancer therapy and inhibition of metastasis.

@article{Xu2019ASN,
  title={A switchable NO-releasing nanomedicine for enhanced cancer therapy and inhibition of metastasis.},
  author={Y. Xu and Hao Ren and Jiwei Liu and Yonglu Wang and Zhengjie Meng and Zhanjie He and W. Miao and G. Chen and Xueming Li},
  journal={Nanoscale},
  year={2019},
  volume={11 12},
  pages={
          5474-5488
        }
}
Clinical chemotherapy for cancer is limited by the physiological barrier of tumors, resulting in low drug delivery to tumors, poor efficacy of drugs and inability to block tumor metastasis. Here we developed an intelligent switchable nitric oxide (NO)-releasing nanoparticle, IPH-NO, which loads a photosensitizer (IR780) and the chemotherapy drug paclitaxel (PTX) into NO donor-S-nitrosated human serum albumin (HSA-NO). NO exhibits two effects based on its concentration: enhancement of… Expand
Glutathione depletion and dual-model oxygen balance disruption for photodynamic therapy enhancement.
Recent progress in nanomedicine for enhanced cancer chemotherapy
Emerging nanotaxanes for cancer therapy.
Synergy of hypoxia relief and heat shock protein inhibition for phototherapy enhancement
...
1
2
3
...

References

SHOWING 1-10 OF 56 REFERENCES
Enhanced tumor therapy via drug co‐delivery and in situ vascular‐promoting strategy
Co‐delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy
...
1
2
3
4
5
...